francesa

FDA approves Indian firm Alembic’s generic of Teva’s Diamox

pharmafile | February 20, 2019 | News story | Research and Development ANDA, Alembic, Gujurat, US FDA, diamox, generics 

The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, a medication used for the treatment of various conditions including glaucoma, epilepsy, altitude sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure.

The FDA granted the drug approval under the Abbreviated New Drug Application (ANDA) application scheme for new generic drugs.

The US regulator granted approval to Alembic’s Acetazolamide Extended-Release Capsules, 500 mg which are therapeutically equivalent to Teva’s listed drug product Diamox Sequels, 500 mg.

The drug is indicated for adjunctive treatment of chronic simple glaucoma, secondary glaucoma, and pre-operatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

The capsules had an estimated market worth $13.1 million for the 12 months ending in December 2018.

As of now, Alembic have a total of 87 separate ANDA approvals, 74 of which are final approvals and 13 of which are tentative from the FDA.  

Louis Goss

Related Content

Leading pharmaceutical companies sued in US for conspiring to drive up generics prices

26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce …

drugs

Trump signs deal with generics company Phlow Corp to help shift drug manufacturing to the US

The Trump administration will sign a $354 million deal with the generics company Phlow Corp …

ny

How the intended role of generic medicines is being undermined in America

The introduction of a generic medicine should, in theory, incentivise companies to lower the price of …

Latest content